Transforming Traditional Medical Affairs
The 2nd Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients.
Whilst Gene Therapies are set to transform treatment paradigms, their complex nature and high price tag presents unique challenges. Learn how the global leaders of the gene therapy world are transforming the traditional role of medical affairs, from reactive to proactive strategic partners to launch gene therapy products more efficiently and effectively than ever before.
Join Orchard Therapeutics, PTC Therapeutics, Sanofi Genzyme and others as we start to define both the role and value of Medical Affairs from early development of gene therapies right the way to a launch environment.
Whether it is learning how to educate and upskill cross-functional teams or tailoring engagement strategies with external HCPs, regulators and patient advocates, join us to determine how best to create a cohesive and streamlined launch strategy specifically for gene therapy products.
We will delve into the unique challenge encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch regulatory scrutiny, equipping you with the insights required to for a successful and patient-centric launch.
Your Expert Speakers Include:
Senior Director, US Gene Therapy, Therapeutic Area Lead
Vice President, Head of Global Medical Affairs
Astellas Gene Therapies
Vice President, Medical Affairs
Castle Creek Biosciences
Vice President, Global Medical Team Lead, Haemophilia, Endocrine In-born Errors of Metabolism and Transplantation
Senior Director Medical Managed Care
Senior Director, Medical Affairs
Health & Safety
The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*. For further information around Health and Safety onsite, please visit our FAQ here.
*Please note, this is subject to change at any time without prior notice.
Who Attended in 2021?
Hear What Our Audience Say
“Great experience where I learned a lot from experts who were sharing their drive and best practices in the gene therapy MA environment”
Wim Weyenberg, Head of Medical Affairs & Operations, UCB
“Enriching and inspiring experience, an highly effective and interactive digital event with thought leaders sharing insights, experiences and vision on the key strategic role of Medical Affairs in delivering gene therapy to patients.
Eleonora Russo, Director Rare Disease Medical, Pfizer
“We really enjoyed the partnership opportunity and look forward to see what lasting relationships might develop from the conference. It was great to be able to share our perspective with leaders in MA.
Crecia Magee, President & Principal Talent Executive, PharmaFinders